North America Generic Drug Market to Reach $315.5 billion by 2035, Driven by Expanding Access to Affordable Therapies

North America generic drug market was valued at $176.6 billion in 2024 and is projected to reach $315.5 billion by 2035, growing at a CAGR of 5.5% during the forecast period (2025–2035). The North America generic drug market is driven by continuous advancements in pharmaceutical manufacturing, strong regulatory oversight, and a growing emphasis on cost-effective healthcare delivery. Stringent approval frameworks established by the US Food and Drug Administration (FDA) and Health Canada encourage manufacturers to focus on bioequivalence, quality consistency, and supply-chain reliability. Innovation in formulation science, complex generics, and injectable and specialty dosage forms is enabling broader treatment access across chronic, acute, and specialty disease areas, while supporting healthcare systems in managing rising prescription volumes and cost pressures.

Browse the full report description of “North America Generic Drugs Market Size, Share & Trends Analysis Report, By Application (Cancer, CVD, Musculoskeletal Diseases, Infectious Diseases, Neurology, Diabetes, and Others), By Route of Administration (Oral, Topical, Injectable, and Inhaler), Forecast Period (2025-2035)” of https://www.omrglobal.com/industry-reports/north-america-generic-drugs-market

Estimated Healthcare Cost Savings from Generic Drug Approvals in North America (2018–2023)

According to the United States Food and Drug Administration (USFDA), the estimated cost savings generated from generic drug approvals, highlight the critical role of generics in strengthening the North America generic drug market. Between 2018 and 2023, annual savings from newly approved generics consistently ranged from approximately $10 billion to nearly $25 billion, underscoring the substantial economic impact of ANDA approvals on healthcare spending. These sustained savings reinforce strong payer and policy support for generic substitution, encourage faster market entry of generics following patent expirations, and drive continued investment by manufacturers in regulatory-compliant production.

Innovation Leaders Transforming the North America Generic Drug Market

The key players in the North America generic drug market include Dr. Reddy’s Laboratories Ltd., Sandoz (a Novartis division), Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Viatris Inc., among others. Companies operating in the North America generic drug market are driving innovation through advanced manufacturing processes, bioequivalence-focused formulation development, and improved quality and stability profiles. These efforts support cost-effective drug production, supply reliability, and adherence to stringent regulatory standards set by the US Food and Drug Administration (FDA), while addressing rising demand for affordable therapies across chronic and acute disease segments.

• In December 2025, Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, received FDA approval and launched its generic version of Victoza, Liraglutide Injection, in a 6 mg/mL dosage in the US. Liraglutide Injection, a Glucagon-Like Peptide-1 (GLP-1) product, is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus.

• In June 2024, Teva Pharmaceuticals, Inc., a US affiliate of Teva Pharmaceutical Industries Ltd., announced the launch of an authorized generic of Victoza1 (liraglutide injection 1.8mg) in the US. This launch adds to Teva’s continued commitment to its complex generic medicine portfolio. Liraglutide injection is indicated to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus and reduce the risk of cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2024
• Forecast period- 2025-2035
• Segment Covered-
  • By Route of Administration
  • By Application
• Competitive Landscape - Dr. Reddy’s Laboratories Ltd., Sandoz (a Novartis division), Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Viatris Inc, among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

North America Generic Drug Market Report Segment

By Route of Administration

• Oral
• Topical
• Injectable
• Inhaler

By Application

• Cancer
• CVD
• Musculoskeletal Diseases
• Infectious Diseases
• Neurology
• Diabetes
• Others

North America Generic Drug Market Report Segment by Region

• US
• Canada

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/north-america-generic-drugs-market